France Aims for 80% Biosimilar Penetration by 2022

Published date15 January 2018
Law FirmGoodwin
Subject MatterPrescription Drugs,Biosimilars,France,Pharmaceutical Industry

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT